Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Small cell carcinoma of the uterine cervix: clinical outcome of concurrent chemoradiotherapy with a multidrug regimen.
Tokunaga H, Nagase S, Yoshinaga K, Tanaka S, Nagai T, Kurosawa H, Kaiho-Sakuma M, Toyoshima M, Otsuki T, Utsunomiya H, Takano T, Niikura H, Ito K, Yaegashi N. Tokunaga H, et al. Among authors: kaiho sakuma m. Tohoku J Exp Med. 2013 Jan;229(1):75-81. doi: 10.1620/tjem.229.75. Tohoku J Exp Med. 2013. PMID: 23269283 Free article. Clinical Trial.
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Takano T, Niikura H, Ito K, Nagase S, Utsunomiya H, Otsuki T, Toyoshima M, Tokunaga H, Kaiho-Sakuma M, Shiga N, Nagai T, Tanaka S, Otsuki A, Kurosawa H, Shigeta S, Tsuji K, Yamaguchi T, Yaegashi N. Takano T, et al. Among authors: kaiho sakuma m. Int J Clin Oncol. 2014 Oct;19(5):897-905. doi: 10.1007/s10147-013-0627-5. Epub 2013 Oct 24. Int J Clin Oncol. 2014. PMID: 24149774
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y. Shoji T, et al. Among authors: kaiho sakuma m. Int J Clin Oncol. 2022 Dec;27(12):1874-1880. doi: 10.1007/s10147-022-02246-1. Epub 2022 Oct 10. Int J Clin Oncol. 2022. PMID: 36214925
Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study).
Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T, Matsumura Y, Shimizu D, Terada Y, Seino M, Ohta T, Nagase S, Shigeta S, Tokunaga H, Shimada M, Kaiho-Sakuma M, Furukawa S, Soeda S, Watanabe T, Takahashi F, Yokoyama Y. Shoji T, et al. Among authors: kaiho sakuma m. Cancers (Basel). 2024 Nov 12;16(22):3801. doi: 10.3390/cancers16223801. Cancers (Basel). 2024. PMID: 39594756 Free PMC article.